Abstract
Background: Interleukin-8 (IL-8) primarily regulates cytotoxicity- and local immune response, antibody production, cellular immunity, and delayed hypersensitive inflammation. Emerging evidences suggest that IL-8 polymorphisms are strongly linked to various cancer risks, however, above correlation requires further confirmation.
Methods and Results: We screened and analyzed the aforementioned relationship from relevant published sources including Embase, PubMed, Chinese database, Google Scholar, and Web of Science till Jun 25, 2023. Associated strength analysis was employed through odds ratios and 95% confidence intervals. In addition, serum IL-8 expression about prostate cancer patients was detected by ELISA method. In all, we reviewed 104 case-control investigations, involving 26,029 cancer incidences and 31,577 healthy controls. Firstly, we demonstrated a strong correlation between the +2767 polymorphism and augmented cancer risk. Additionally, the +781 polymorphism elicited a strong increase in cancer risk among Caucasians. However, based on our cancer type subgroup analysis, there had markedly reduced association for hepatocellular carcinoma. Then, enhanced correlation was observed in all cancer samples for -251 polymorphism. Besides, we also revealed comparable results among in the Mixed/Asian populations, gastric cancer, lung cancer, hospital-based subgroup, and genotype method subgroup. Finally, -251 individuals carried AA/AC genotype had higher expression of IL-8 in serum than carrying CC individuals from prostate cancer patients.
Conclusion: Three IL-8 polymorphisms (+2767, +781 and -251) were intricately linked to cancer risk. Additional, -251 polymorphism may influence the expression of IL-8 in prostate cancer patients. Therefore, these polymorphisms may be excellent candidates for tumor biomarkers in the future.